Barentz Acquires Gangwal in India
Barentz International, a leading global life science ingredients distributor announced an agreement to acquire a majority stake in the distribution
Author: Tamas Sohajda
Cyclolab R&D Director
Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant
Gilead has conducted an analysis of genetic information currently available for the Omicron variant and found no additional prevalent mutations
Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through
Cyclo Therapeutics Submits IND Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease
Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
Parkinson’s Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxypropyl-β-Cyclodextrin Treatment
OrganoTherapeutics in collaboration with University of Luxemburg has published interestingin vitro and in vivo results on the effects of HPBCD
Alveron Pharma raises a further EUR 3.9 million to progress first in class cyclodextrin drug
Alveron Pharma BV (Nijmegen, The Netherlands) has raised a further EUR 3.9 million to fund the continued development of OKL-1111,
Underdog Closes $10M Financing Round – the next cyclodextrin can be developed further as active
Underdog Pharmaceuticals, a key investment of Michael Greve’s rejuvenation biotech VC Kizoo, has closed a $10 million round of capital.
Marinus Announces FDA Acceptance for Filing and Priority Review of NDA for SBECD-enabled Ganaxolone in CDKL5 Deficiency Disorder
Marinus Pharmaceuticals, Inc. , a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine
Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced
Underdog Pharmaceuticals Awarded ‘Innovation Passport’ by UK Regulators
Underdog Pharmaceuticals, Inc. (Underdog), a pre-clinical stage pharmaceutical company focusing on the treatment and reversal of age-related diseases, has been